Risk factors

Chaince Digital Holdings faces concentration risk from transaction-based financial advisory revenues and a limited client base. Its broker-dealer subsidiary Chaince Securities is heavily regulated by FINRA and the SEC. Cross-border operations span North America, Greater China, and Southeast Asia, exposing the firm to PRC regulations and digital asset volatility.

Celcuity added $338.8M in debt, including $201.3M in Senior Notes and $130M in Term Loans, ramping up commercial and financing risks.

New risks address clinical-data privacy limits, artificial intelligence, and uncertainty over Securities Act litigation forums.

CapsoVision faces substantial net losses of $25.3M in 2025 and going concern warnings from its auditors. The company relies heavily on single-source suppliers in Taiwan and Japan for its CapsoCam medical devices. Commercial growth depends on FDA clearances for CapsoCam Colon and proprietary AI diagnostic tools.

CaliberCos added a new Treasury Reserve Policy focused on acquiring, holding, and staking LINK digital assets.

Terminated the Bayer license agreement for Ovaprene, requiring a new commercial partner. Launched the DARE to PLAY 503B compounded drug strategy using outsourcing facilities and telehealth platforms. Faced FDA regulatory scrutiny regarding radical transparency and public release of complete response letters.

DBV prepares for U.S. commercialization of the Viaskin Peanut patch following positive Phase 3 VITESSE results in children aged 4 to 7. Stallergenes Greer intends to discontinue Palforzia commercialization in July 2026. The company relies heavily on Sanofi and FAREVA for manufacturing.

Journey Medical added new risk disclosures addressing import tariffs from India, FDA funding cuts, and changing presidential administration policies. The company faces ongoing generic competition threats and patent challenges for products like Qbrexza, Amzeeq, Zilxi, and Emrosi. Fortress maintains voting control through Class A common stock, potentially deterring control changes.

Dermata shifted focus from prescription clinical trials to launching its Tome skincare line using OTC monograph pathways.

Adoption of artificial intelligence introduces new compliance, data privacy, and security risks to operations.

Gain Therapeutics added significant risk disclosures regarding US government shutdowns impacting the SEC and FDA, international tariffs, and the newly enacted BIOSECURE Act impacting its reliance on Chinese partners such as WuXi AppTec.

The company relies on interest income from marketable securities to generate net income while facing working capital deficits. Management must complete an initial business combination before May 13, 2026 to avoid liquidation. Initial shareholders control all director appointments and own 20% of shares.